Latest Kaiser Health News Stories
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat — or even falling — in many Western states, where the drug has not yet been as common as other parts of the country.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Genetic testing firms declare bankruptcy and wipe out debt to the federal government.
Researchers estimate that 25 percent of people ages 65 to 69 take at least five prescription drugs to treat chronic conditions. But some doctors are trying to teach others about “deprescribing” or systematically discontinuing medicines that are inappropriate, duplicative or unnecessary.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
Based on research conducted at the University of Michigan’s medical center, a group of surgeons developed a strategy to help post-surgical patients from misusing or abusing their prescription painkillers.
The hurricane closed pharmacies and clinics for a week or longer. Floodwaters spoiled drugs. People who fled to other states couldn’t get their prescriptions filled for HIV medicine.
The price for Pfizer’s Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.
Medicare and insurers struggle to oversee a booming business in testing urine samples. In some cases, pain doctors’ lack of follow-through can turn fatal.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Alice Ollstein of Talking Points Memo and Sarah Jane Tribble of Kaiser Health News discuss some of the under-covered health stories of the past several weeks, including drug price issues, the opioid epidemic and women’s reproductive health.
Following minor surgery, KHN’s consumer columnist sees how easily doctors offer pain pills, fueling epidemic of opioid addiction.
In an effort to reduce drug costs and increase efficiency, Massachusetts is seeking federal approval to implement a new approach to how the state’s Medicaid program covers prescription medications.
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.